Lynn Seely - 11 Aug 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
President and CEO, Director
Signature
/s/ Allison Peth, Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
11 Aug 2025
Net transactions value
-$8,313
Form type
4
Filing time
13 Aug 2025, 21:10:46 UTC
Previous filing
21 Jul 2025
Next filing
22 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Seely Lynn President and CEO, Director C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO /s/ Allison Peth, Attorney-in-Fact 13 Aug 2025 0001327111

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Sale $4,116 -391 -1.1% $10.53 35,234 11 Aug 2025 Direct F1, F2, F3
transaction LYEL Common Stock Sale $4,197 -406 -1.2% $10.34 34,828 12 Aug 2025 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F3 On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
F4 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F5 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F6 On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.